Blueprint Medicines (BPMC) Misses Q4 EPS by 2c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($2.65), $0.02 worse than the analyst estimate of ($2.63). Revenue for the quarter came in at $38.78 million versus the consensus estimate of $34.16 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Nike (NKE) PT Raised to $55 at BTIG
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets